Sarepta jumps into the CRISPR fray with Duke gene-editing pact
October 31, 2017 at 09:44 AM EDT
The Cambridge biotech said the agreement has the potential to produce a drug for Duchenne muscular dystrophy that can help all patients with the muscle-wasting disease.
